• Net benefit of venous thromboprophylaxis (VTE) in patients hospitalized for infections is unknown.
Summary. Background: Despite the well-established association between infection and venous thromboembolism (VTE), there are few data specifically assessing the efficacy and safety of the VTE prophylaxis strategies for patients hospitalized for acute infectious diseases. Objectives: To estimate the incidence of VTE and bleeding outcomes, comparing prolonged prophylaxis with rivaroxaban 10 mg daily for 35 days with enoxaparin 40 mg daily for 10 days. Patients/Methods: A subgroup analysis of patients hospitalized for acute infectious diseases in the MAGELLAN trial was performed. The primary efficacy outcome was the composite of asymptomatic proximal or symptomatic VTE at days 10 and 35. The principal safety outcome was the composite of major or clinically relevant non-major bleeding. Results: Three thousand one hundred and seventythree patients with acute infectious diseases leading to hospitalization were randomized to either rivaroxaban (n = 1585) or enoxaparin/placebo (n = 1588), and received at least one dose of study medication. At day 10, primary composite efficacy outcomes did not differ between prophylaxis strategies (rivaroxaban, 2.7%; and enoxaparin, 3.7%). At day 35, there were fewer VTE events with rivaroxaban (4.2%) than with enoxaparin (6.6%) (relative risk [RR] 0.64; 95% confidence interval [CI] 0.45-0.92). Patients with pulmonary infections randomized to rivaroxaban had a lower incidence of VTE both at 10 days (RR 0.50, 95% CI 0.28-0.90) and at 35 days
Introduction
Venous thromboembolism (VTE) (i.e. deep vein thrombosis [DVT] or pulmonary embolism [PE] ) is a major public health problem, with > 500 000 incident or recurrent VTE events occurring annually in the United States [1, 2] . Survival among patients with incident and recurrent VTE is significantly reduced, especially after PE [3] . In order to improve outcomes, targeted efforts to reduce incident VTE in patients with acute infectious diseases may be advantageous.
Of all VTEs occurring in the community, half are related to current or recent hospitalization for surgery or medical illness [4] . Thus, hospitalization of acutely ill patients is associated with an eight-fold increase in VTE risk. Currently, VTE prophylaxis duration is limited to the period of hospitalization [5] , but most VTE events occur within the first month following hospital discharge [6] . If all hospitalized patients received universally effective prophylaxis, one-quarter of the VTE burden in the community would be prevented [7] . To further reduce the VTE burden, better prophylaxis strategies are needed, which may include prolonging VTE prophylaxis beyond hospital dismissal.
VTE is a common complication of acute infectious diseases, which increase VTE risk by two-fold to 32-fold [8] [9] [10] . Despite this well-established association [8] [9] [10] , there are few data specifically addressing VTE prophylaxis in patients recently hospitalized with acute infectious diseases [11] . Indeed, infection-associated VTE might account for a substantial burden of incident or recurrent VTE in the community currently labeled as 'unprovoked' [8] [9] [10] .
To address these limitations, a subgroup analysis of patients hospitalized with infectious diseases in the MAGELLAN trial [12] data was performed to estimate: (i) the VTE incidence among those recently hospitalized with acute medical illness treated with prophylactic doses of either rivaroxaban or enoxaparin; (ii) specific infection locations as risk factors for VTE after controlling for other traditional risk factors; and (iii) the efficacy and safety of extended-duration prophylaxis with rivaroxaban as compared with limited-duration enoxaparin to reduce VTE.
Methods

Study population
The design, methods and primary results of the MAGEL-LAN trial have been described previously [13, 14] . Briefly, the MAGELLAN trial was a randomized, double-blind, active comparator-controlled, parallel-group efficacy and safety multinational clinical trial comparing rivaroxaban (10 mg daily) administered for 35 days with enoxaparin (40 mg daily) administered for 10 days followed by placebo for the prevention of VTE. Eligible participants were aged ≥ 40 years with reduced mobility and had recently been hospitalized for acute medical illness. The current subgroup analysis comprised those MAGELLAN trial participants with acute infectious diseases leading to hospitalization. The current analysis was not prespecified as a part of the original trial methodology. Infections were allocated by location into one of the following categories: bacteremia/sepsis; head, eyes, ear, neck, and throat (HEENT); pulmonary; gastrointestinal; genitourinary; skin/soft tissue; and other sites. Data collection and statistical analyses were performed by the sponsors (Janssen Research and Development LLC and Bayer US LLC). The MAGELLAN trial (NCT00571649) was conducted in accordance with Good Clinical Practice Guidelines and under the guiding principles detailed in the Declaration of Helsinki.
Outcome definitions
All outcomes were assessed by an independent, central adjudication committee whose members were unaware of the study assignments. There were two coprimary efficacy outcomes. The first was a composite of asymptomatic proximal DVT, symptomatic proximal or distal DVT, symptomatic non-fatal PE or death related to VTE from day 1 to day 15 (day 10 analysis). The second was this same composite outcome from day 1 to day 41 (day 35 analysis). The day 10 analysis was prespecified to be a non-inferiority analysis, and the day 35 analysis was prespecified to be a superiority analysis. Mandatory lowerextremity compression ultrasonography was performed at day 10 and day 35. The secondary efficacy outcomes were symptomatic VTE and VTE-related death.
The principal safety outcome was a composite of major bleeding plus clinically relevant non-major bleeding observed no later than 2 days after administration of the last dose of double-blind study medication. The definitions of major bleeding and clinically relevant non-major bleeding have been previously described [13, 15] . Major bleeding was defined as bleeding leading to a ≥ 2 g dL À1 fall in hemoglobin or a transfusion of ≥ 2 units of packed red blood cells or whole blood, bleeding into a critical site (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or bleeding leading to death. Non-major clinically relevant bleeding was defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact with a physician, temporary cessation of study treatment, discomfort for the patient such as pain, or impairment of activities of daily life. Overt bleeding episodes that did not meet the criteria for either of these outcomes, adverse events that occurred during the treatment period and abnormal laboratory results were also evaluated. In the current analysis, net clinical benefit or harm was assessed as the composite of symptomatic VTE, VTE-related death and major bleeding at day 10 and at day 35.
Statistical analyses
Baseline characteristics were summarized according to treatment group for the safety population defined as all patients who received at least one dose of study medication. The efficacy analysis was performed for the modified intent-to-treat population, which included patients who received at least one dose of study medication and had an adequate assessment of venous thromboembolic disease. The relative risk (RR) ratio of the VTE incidence (rivaroxaban versus enoxaparin) was estimated on the basis of a stratified estimator with Mantel-Haenszel weights (based on sample sizes by geographical region). The RR and the corresponding two-sided 95% confidence intervals (CIs) were additionally tabulated by infection type. For handling of zero events, a continuity correction factor of 0.5 was added to zero count cells [16] . Further exploratory analysis was performed with a logistic regression model with terms for treatment and geographical region included in the model and backward selection with a threshold level of 5% for retaining the effects in the model. The following covariate characteristics were included: number of medical history-relevant thromboembolism risk factors -duration of complete immobilization after randomization (in days), duration of complete immobilization before and after randomization (in days), severe varicose veins, chronic venous insufficiency, history of cancer, history of VTE, history of heart failure New York Heart Association (NYHA) class III or IV, thrombophilia (hereditary or acquired), recent major surgery, recent serious trauma, hormone replacement therapy, advanced age (≥ 75 years), morbid obesity (body mass index of ≥ 35 kg m À2 ), acute infectious disease contributing to hospitalization, acute ischemic stroke with paresis, and diabetes mellitus. Kaplan-Meier curves displaying the cumulative rate of treatment-emergent major and nonmajor clinically relevant bleeding events for rivaroxaban and enoxaparin / placebo treated patients were generated at day 10 and at day 35. Rivaroxaban and enoxaparin Kaplan-Meier curves were generated for bleeding event at day 10 and day 35. All statistical analyses were exploratory; reported P-values should be interpreted with this in mind, and no adjustments for multiplicity were made.
Results
Study populations
A total of 8428 patients were enrolled at 556 sites in 52 countries. Of these, 3173 patients hospitalized for treatment of an acute infectious disease were randomized and treated with at least one dose of study medication. The numbers of patients excluded from the modified intent-totreat analysis at day 10 and at day 35 in the rivaroxaban group were 348 (22.0%) and 454 (28.6%), respectively, and 323 (20.3%) and 413 (26.0%) were excluded in the DVT, deep vein thrombosis; SD, standard deviation; VTE, venous thromboembolism. *Patients who received at least one dose of study medication. †The body mass index is the weight in kilograms divided by the square of the height in meters. ‡Creatinine clearance levels were calculated with the equation of Cockcroft and Gault. The values shown are day 1 levels. §Race was self-reported. ¶The D-dimer level was calculated in the safety population (all patients who underwent randomization and received at least one dose of study medication), which included 7998 patients (3997 in the rivaroxaban group and 4001 in the enoxaparin group). The normal range is < 0.5 lg mL-1. **Included are patients with a history of New York Heart Association heart failure class III or IV.
enoxaparin group. The majority of them were excluded because of inadequate VTE assessment; 633 patients were excluded at day 10, and 840 were excluded at day 35. Detailed descriptions of the specific infectious disease groupings and infection types are provided in Tables S1  and S2 . Demographic characteristics, clinical characteristics and VTE risk factors are presented for 1585 patients in the rivaroxaban group and 1588 in the enoxaparin group (Table 1 ). The two treatment groups did not differ by median age, gender, or hospital duration. More than 45% of enrolled patients in the infectious disease subgroup had two or more acute medical conditions prompting hospitalization.
Infection type did not differ by treatment assignment among MAGELLAN patients ( Table 2) . Pulmonary infections were the most common infections, affecting more than half of the patients (n = 1859, 58.6%). Genitourinary infections (11.4%) and skin/soft tissue infections (15.3%) were also common. Other infection types included bacteremia/sepsis (7.8%), HEENT (7.8%), gastrointestinal (2.4%), and other infections (2.6%).
Efficacy outcomes
Among patients hospitalized with an acute infectious disease, the VTE incidence during the 10-day period for those patients randomized to rivaroxaban (2.7%) and those randomized to enoxaparin (3.7%) did not differ (RR 0.74; 95% CI 0.48-1.14; P = 0.169) ( Table 3) . At day 35, however, the composite primary efficacy outcome was significantly lower for those patients randomized to rivaroxaban (4.2%) than for those randomized to enoxaparin (6.6%) (RR 0.64; 95% CI 0.45-0.92; P = 0.014). Patients hospitalized with pulmonary infections randomized to rivaroxaban experienced significantly fewer efficacy outcomes at both day 10 and day 35. Patients hospitalized with bacteremia/sepsis receiving rivaroxaban showed a trend towards improved efficacy outcomes at day 35 (P = 0.07). Primary efficacy outcomes did not differ by other sites of infection.
Patients with pulmonary infections randomized to rivaroxaban also experienced fewer secondary composite outcome events (symptomatic VTE and VTE-related death) at day 10 (Table 4) . Composite secondary efficacy outcomes were lower at day 35, in favor of extended rivaroxaban prophylaxis. Multivariate analysis demonstrated that rivaroxaban was more effective at day 35 for the prevention of VTE after adjustment for VTE risk factors (Table 5) .
Safety outcomes
The primary safety outcome at day 35 occurred more frequently in patients receiving rivaroxaban prophylaxis (RR 2.42; 95% CI 1.60-3.66; P ≤ 0.0001) ( Table 6) . Major bleeding and all confirmed bleeding also differed significantly between the two prophylaxis strategies (Fig. 1A,B) . For those patients hospitalized with pulmonary infections, both the primary safety outcome and major bleeding outcome occurred more frequently in the rivaroxaban group. For those with sepsis/bloodstream infections, the primary safety endpoint was more frequent in the rivaroxaban group, but the difference was not significant (P = 0.06). The cumulative rate of bleeding was similar up to day 10 and day 35.
There were five fatal bleeding events, all occurring in the rivaroxaban group. Intracranial bleeding was observed in one rivaroxaban recipient. Gastrointestinal bleeding was observed in 30 (1.9%) rivaroxaban recipients and in 15 (0.9%) enoxaparin recipients. Pulmonary bleeding was observed in four rivaroxaban recipients.
Net clinical benefit and harm
The net clinical benefit represents the combination of symptomatic DVT, non-fatal PE, VTE-related deaths, including fatal PE and deaths for which PE could not be excluded as a cause, and major bleeds. By day 10, for all infectious diseases, VTE events and major bleeding had occurred in 0.6% and 1.1% of rivaroxaban recipients and in 1.4% and 0.4% of enoxaparin recipients. The numbers needed to treat and harm with rivaroxaban at day 10 were 144 and 140, respectively. By day 35, VTE events and major bleeding had occurred in 1.3% and 1.7% of rivaroxaban recipients, and in 2.4% and 0.5% of enoxaparin recipients, respectively. The numbers needed to treat and harm with rivaroxaban at day 35 were 85 and 84, respectively.
By day 10, for pulmonary infections, VTE events and major bleeding had occurred in 0.5% and 0.9% of rivaroxaban recipients and in 1.7% and 0.5% of enoxaparin recipients respectively. By day 35, VTE events and major bleeding events had occurred in 1.5% and 1.8% of rivaroxaban recipients and in 2.6% and 0.6% of enoxaparin recipients, respectively. The numbers needed to treat and harm with rivaroxaban at day 30 were 88 and 82, respectively. HEENT, head, ears, eyes, nose, and throat. *Patients who received at least one dose of study medication.
Cumulative incidence of asymptomatic and symptomatic VTE events
The cumulative incidence of asymptomatic and symptomatic VTE events for the modified intent-to-treat population was similar between the groups at day 10. By day 35, rivaroxaban receipients experienced fewer events than enoxaparin recipients (P = 0.0153) ( Fig. 2A,B) .
Discussion
The principal finding of this subgroup analysis of the MAGELLAN trial data [12] was that prophylaxis with rivaroxaban reduced the occurrence of VTE among patients hospitalized with acute infectious diseases after adjustment for known risk factors. Patients admitted with pulmonary infections (RR 0.54) appeared to benefit most from rivaroxaban prophylaxis. Other infections, combined, contributed to a decreased VTE risk (RR 0.63), after adjustment for the other risk factors. These findings are similar to the overall MAGELLAN trial results. In the original MAGELLAN trial [12] , which randomized 8101 patients, there was no difference, at 10 days, in the rates of primary efficacy events, which occurred in 2.7% of both the rivaroxaban and enoxaparin groups. At 35 days, there CI, confidence interval; DVT, deep vein thrombosis; HEENT, head, eyes, ears, nose, and throat; PE, pulmonary embolism; VTE, venous thromboembolism. *The secondary composite efficacy outcome was defined as the incidence of the composite of symptomatic proximal or distal DVT, symptomatic PE, symptomatic non-fatal PE, and or VTE-related death to day 10 AE 4 and day 35 AE 4. †Patients who received at least one dose of study medication.
was an absolute reduction in the primary efficacy endpoint by 1.3%, favoring rivaroxaban. This came at the expense of an increased rate of bleeding at both time points for those patients randomized to rivaroxaban. In the MAGEL-LAN trial [12] , more than half of the participants enrolled were hospitalized for acute infection. This is in contrast to the results of the ADOPT trial [17] , which also enrolled acutely ill hospitalized patients randomized to receive either apixaban 2.5 mg twice daily for 30 days or enoxaparin 40 mg once daily for up to 14 days. In general, these two trials were very similarly designed. However, the results of the ADOPT trial were largely negative. Extended-duration apixaban was not superior to, and indeed resulted in significantly more major bleeding events, than enoxaparin. Both agents inhibit activated factor X (FXa), and hence one might anticipate similar efficacy. The ADOPT trial, however, enrolled considerably fewer patients with acute infectious diseases (1447 of 6528; 22.2%) [17] . Our data demonstrate that specific medical indications for hospitalization are associated with different levels of VTE risk. Identification of independent VTE risk factors and estimating the magnitude of the associated risk may be helpful when strategies for prophylaxis delivery are devised. Granularity of VTE risk assignment may be important, whereby simply combining similar variables together in this context may result in important risk differences between variables being missed. In the current study, different infection locations were not associated with the same VTE risk, and nor did patients have the same response when prescribed one of two prophylaxis strategies. For example, patients with pulmonary infections and sepsis responded well to rivaroxaban as opposed to enoxaparin. Prophylaxis with this medication was less effective in patients with other infections. The novel finding of the current study is that extended VTE prophylaxis may not be warranted for all infections, but may be very helpful for some. Prior reports have shown an association between infection and increased VTE risk after adjustment for known risk factors [18] , with the highest risk being demonstrated in those with intra-abdominal infection (odds ratio [OR] 17), followed by systemic bloodstream infection (OR 10), lower respiratory infection, such as pneumonia (OR 3.5), and symptomatic urinary tract infection (OR 2.0). It has been reported that individuals with pneumococcal pneumonia have a 1.97-fold risk of developing PE and a 1.78-fold risk of developing leg DVT [19] . The incidence rates of DVT and PE were highest in the first 4 weeks after the pneumonia diagnosis. However, these studies did not evaluate different VTE prophylaxis strategies, and especially extended prophylaxis beyond hospital dismissal. Our current findings support extended VTE prophylaxis with rivaroxaban for those patients recently hospitalized with either pulmonary infections or sepsis.
The relationship between infection and thrombosis is complex. Systemic infection is known to promote thrombosis through endothelial injury, tissue factor-induced coagulation factor activation, downregulation of the endogenous anticoagulant pathways, and fibrinolysis inhibition [20] [21] [22] [23] . Venous thrombosis, in particular, has been linked to neutrophil activation with the release of neutrophil extracellular traps (NETs) [23] [24] [25] [26] [27] . Upon activation, polymorphonuclear cells are known to excrete a fine fibrillary network, composed of NETs, which then contributes to endothelial cell release of tissue factor [28, 29] . NETs are also known to promote the initiation of platelet adhesion, activation and aggregation through a P-selectin mediated pathway [26, 30, 31] . Colocalization of FXII has been postulated to promote coagulation propagation at the site of inflammation through this mechanism. Moreover, human studies have demonstrated that elevated levels of circulating nucleosomes and elastase-a 1 -antitrypsin complexes are associated with a three-fold increased risk of venous thrombosis [32] . These measures have been proposed as useful screening tools for thrombotic propensity assessment.
Our study has several important strengths and limitations. The MAGELLAN trial [12] was a carefully constructed randomized controlled trial with a doubledummy double-blind multicenter methodology. Because of the unique features of the trial, our study avoids referral bias and other potential distortions, including a toohealthy population. All VTE cases met strict criteria for objectively diagnosed acute DVT and/or PE based on imaging rather than depending on administrative codes. Infection within 90 days prior to the index date was confirmed by reviewing the medical records. We adjusted for all potential VTE risk factors when testing for associations between infections and VTE. We included all infection sites, and each infection location was equally distributed between treatment allocations. Infection categorization was performed at the time this subgroup analysis was conducted. Nonetheless, the notable differences between the two groups add validity to the finding of efficacy among different infections, particularly pneumonia and sepsis. There are several important limitations. The current study was retrospectively constructed and analyzed. With regard to the specific location of infection, the study is substantially underpowered (as reflected by the low number of events and wide CIs), and these results should therefore be interpreted with caution. This analysis was not part of the original study design. Therefore, it may be subject to interpretation bias. The infection categorization was performed post hoc. We therefore cannot exclude the possibility of bias in this categorization. Because of the difficulty in dating the onset of an infection, we were unable to test the association of infection duration (within the preceding 90 days) with VTE. Furthermore, because of the retrospective nature of the analysis, it was not possible to analyze specific bacteriology. It is known that different bacteria interact uniquely with proteins in the coagulation system [33] [34] [35] . Endotoxin from Gram-negative bacteria is a good example of this interaction [36] [37] [38] [39] . A prospective randomized controlled clinical trial focusing only on pneumonia or sepsis would be useful for further clarifying the interaction between infection and VTE disease.
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